Safety and efficacy of Xevinapant (Debio 1143), an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a Phase Ib/II trial in patients failing prior PD-1/PD-L1 treatment

Presented at ESMO 2020

A. Azaro-Pedrazzoli1, V. Moreno2, C. Gomez-Roca3, C. Even4, P. Cassier5, T. Hernandez Guerrero2, M. de Miguel6, I. Korakis3, D. Purcea7, E. Roy7, K. Gollmer7, C. Riff7, S. Szyldergemajn7, E. Calvo6,

  1. Oncology Department, Vall d`Hebron University Hospital Institut d’Oncologia, Barcelona, Spain,
  2. Clinical Research Phase 1 Trials Unit, START Madrid-FJD, University Hospital “Fundacion Jimenez Diaz”, Madrid, Spain,
  3. Medical Oncology and Clinical Research Department, Institut Universitaire du Cancer, Oncopole, Toulouse, France,
  4. Département de Carcinologie Cervicofaciale, Institut Gustave Roussy, Villejuif, France,
  5. Department of Medicine, Centre Léon Bérard, Lyon, France, 6START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain, 7Debiopharm International S.A., Forum après-demain, Lausanne, Switzerland